Project Name Category Date National Annual Savings Download
Pregabalin - Full Report Brand Optimisation Feb 2017 £165,000,000
Alimemazine - Full Report Deprescribing Feb 2017 £17,500,000
Fentanyl Patch - Full Report Brand Optimisation Feb 2017 £10,000,000
Salmeterol - Full Report Brand Optimisation Feb 2017 £8,000,000
Salbutamol Tablets - Full Report Deprescribing Feb 2017 £2,000,000
Phenindione - Full Report Deprescribing Feb 2017 £2,000,000
Salmeterol/FluticasoneMDI - Full Report/td> Deprescribing Mar 2017 £20,000,000
Easyhaler Range - Full Report Brand Optimisation Apr 2017 £15,700,000
Pregabalin - Full Report Brand Optimisation May 2017 £142,000,000
Co-Proxamol - Full Report Deprescribing Mar 2017 £8,400,000
Prednisolone Solution Brand Optimisation May 2017 £8,100,000
Quetiapine XL - Full Report Brand Optimisation Mar 2017 £12,000,000
Galantamine XL - Full Report Brand Optimisation Mar 2017 £4,000,000
Alimemazine - Data Update Deprescribing Jun 2017 £17,500,000
Co-Proxamol - Data Update Deprescribing Jun 2017 £8,400,000
Easyhaler Range - Data Update Brand Optimisation Jun 2017 £15,700,000
Fentanyl Patch - Data Update Brand Optimisation Jun 2017 £10,000,000
Galantamine XL - Data Update Brand Optimisation Jun 2017 £4,000,000
Phenindione - Data Update Deprescribing Jun 2017 £2,000,000
Prednisolone Solution - Data Update Brand Optimisation Jun 2017 £8,100,000
Quetiapine XL - Data Update Brand Optimisation Jun 2017 £12,000,000
Salbutamol Tablets - Data Update Deprescribing Jun 2017 £2,000,000
Salmeterol - Data Update Brand Optimisation Jun 2017 £8,000,000
Salmeterol/FluticasoneMDI - Data Update Deprescribing Jun 2017 £20,000,000
Pregabalin Stock Alert Jul 2017
Quetiapine Stock Alert Jul 2017